The interplay between cancerous cells and immune cells has always been an intriguing topic in medicine and biology. Cancer cells emerge from self-cells through a series of genetic mutations. They often retain self-cells' capacity in being exempt from immune surveillance. Therefore, bringing cancer cells back under the radar of immune system has long been considered as a necessary step toward complete tumor eradication and long-term antitumor protection. Based on this rationale, a series of immunotherapies were designed and many have shown promising results. Some have gone through multiple stages of clinical trials. As a result, a successful immunotherapy is an intricate clinical procedure that affects the function of a myriad of cells. Only comprehensive studies that profile multiple aspects (e.g., cellular abundance, phenotypes, and functions) over time at the finest details can effectively monitor the convoluted immune response induced by therapy. Many recent technical developments aim to provide a solution for comprehensive clinical immune assessment.
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In this book, we compiled a series of high-quality papers that summarize recent developments of immune assessment tool and methodology, as well as new biological findings in tumor immunity and cancer immunotherapy.
The book starts with a number of reviews and research articles that form an update of cancer immunotherapy. Ma et al. The editors thank all authors for their contributions and appreciate the valuable discussions with our reviewers. We wish that this special issue would serve as a reference book to the field and will inspire more thoughts and discussions for future investigation.
